Skip to main content
Ryan D. Cassaday on Muck Rack

Ryan D. Cassaday

Seattle
As seen in: Nature, Wiley Online Library, Taylor & Francis Online, The Lancet, Dove Medical Press, Healio, HemOnc Today, OncLive, Patient Power
Husband of Dr. Emily Stevens MD PhD. ALL Doctor. Product of 2 UW's. Tweets are mine and do not constitute medical advice.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ryan D.

Contact Ryan D., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms

|
By Anna B. Halpern, Megan Othus, Mary-Elizabeth M. Percival, Cristina M Ghiuzeli, Jacob Appelbaum, Paul Hendrie, Ryan D. Cassaday, Max Smith, Kathryn Russell, Bart Scott Verified, Jason Cooper, Joshua R. Veatch, Sioban Keel, Vivian G. Oehler, Erik Kimble, Roland B. Walter, Raya Mawad
| Nature Verified
Abstract Even with new drugs available, how best to treat unfit adults with acute myeloid leukemia (AML) remains uncertain. In a previous trial in such patients, we found high-dose cytarabine-based therapy with CLAG-M yielded higher response rates but no more toxicity than lower-intensity therapy with dose-attenuated CLAG-M.
Open in Who Shared Issue with article?

Patients First: Navigating Asparaginase‐Based Treatment in Young Adults With Acute Lymphoblastic Leukemia

|
By Ryan D. Cassaday, Daniel DeAngelo
| Wiley Online Library Verified
1 Plain Language Abstract This educational program gives healthcare professionals practical tools and information they can use to improve survival and quality of life for young adults living with acute lymphoblastic leukemia (ALL), a type of blood cancer. In the program, real people describe their experiences with ALL. Many young adults with ALL face challenges related to transportation, job and family stress, mental health, and long-term wellness.
Open in Who Shared Issue with article?

Optimizing Asparaginase Treatment for Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia: US Consensus Panel Recommendations

|
By Ibrahim Aldoss, Amir Ali, Ryan D. Cassaday, Emily Curran
| Wiley Online Library Verified
Conflicts of Interest I.A. reports advisory board participation for Acentage, Adaptive, Amgen, Autolus, Jazz Pharmaceuticals, Kite, Pfizer, Syndax, and Takeda; consulting for Amgen, Jazz Pharmaceuticals, Pfizer, and Takeda; and research support from AbbVie, Jazz Pharmaceuticals, and MacroGenics. A.A. reports consulting and participation in advisory boards, speakers' bureau participation, and research funding from Jazz Pharmaceuticals.
Open in Who Shared Issue with article?
See all 27 licensed articles (38 Total)